Myasthenia Crisis as First Presentation of MuSk Positive Myasthenia Gravis: A Case Report
Dipesh Chhetri, Amit Sharma Bhattarai, Pankaj Joshi, Kriti Thapa

TL;DR
A 57-year-old woman's first symptom of Myasthenia Gravis was a myasthenia crisis with severe respiratory issues, highlighting the importance of considering atypical presentations.
Contribution
This case report emphasizes the need to consider Myasthenia Gravis in patients with unexplained respiratory failure and atypical symptoms.
Findings
The patient presented with severe respiratory acidosis and failed extubation, leading to a diagnosis of MuSk-positive Myasthenia Gravis.
Classical symptoms of Myasthenia Gravis were absent at presentation, complicating the initial diagnosis.
The case underscores the importance of neurological evaluation in atypical respiratory presentations.
Abstract
We report a unique presentation of a 57-year-old female presented with severe respiratory acidosis, which was found to be a case of Musk-positive Myasthenia Gravis. Patient presented with depressed level of consciousness and respiratory failure, mandating urgent ventilatory support. She responded well with positive pressure ventilation. However, she persistently failed to maintain adequate ventilation after extubation and had to be reintubated. At presentation, the absence of classical symptoms typical of Myasthenia Gravis posed a diagnostic dilemma, initially obscuring the underlying etiology. However, since there was no other identifiable cause for the inability to maintain ventilation, antibody panels were sent which turned out positive for Muscle specific kinase. This case thus highlights the significance of considering atypical neuromuscular presentations, particularly when…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMyasthenia Gravis and Thymoma · Parkinson's Disease and Spinal Disorders
INTRODUCTION
Myasthenia crisis is a sudden exacerbation of a myasthenia gravis characterized by respiratory fatigue and leading to respiratory failure urgently requiring ventilatory support to prevent death. Myasthenia crisis occurs in 15-20% of patients with myasthenia gravis, most within the first 2 years of diagnosis.^1^ In about 20% of patients, myasthenia crisis is the first manifestation of yet undiagnosed myasthenia gravis.^1^ However, Respiratory failure was the initial presentation in only 2% of patients with MuSK-positive Myasthenia Gravis, highlighting its rarity as a presenting feature.^2^ This case underscores the clinical variability of MuSK-positive MG, presenting with a myasthenic crisis and respiratory failure as the initial manifestation. While ptosis and bulbar symptoms were later elicited, their subtle nature delayed diagnosis. Furthermore, the presence of comorbidities such as diabetes, hypertension, subclinical hypothyroidism, schizophrenia and concurrent lower respiratory tract infection likely contributed to diagnostic challenges, as these conditions can mimic or obscure MG symptoms and complicate clinical assessment.^3^
CASE REPORT
A 57-year-old female presented to the emergency department in November 2023 with an hour-long loss of consciousness, altered sensorium, irritability, refusal to eat or drink, and loss of bowel and bladder control for a day. Her medical history included pulmonary embolism (6 months prior, treated with Rivaroxaban), schizophrenia, diabetes, and hypertension, all controlled under medications.
On examination, she had GCS of E1V1M1, accompanied by reduced chest movements and diminished breath sounds on auscultation. Arterial blood gas analysis showed significant respiratory acidosis with pH 7.1 and pCO2 129.9. The patient was immediately intubated and put on mechanical ventilation. A thorough blood analysis revealed Hb at 11.6, WBC at 10,700, Sodium at 132, Potassium at 4.5, decreased serum calcium at 7.5, Urea/Creatinine at 36/1.6, ESR at 19, and an elevated RBS of 395 mg/dl with 2+ sugar in the urine. Urine acetone was negative. She was started on IV fluids alongside Inj Noradrenaline infusion to manage her hypotension while withholding all her antihypertensives. Concurrently, IV antibiotics Piperacillin/Tazobactam and Levofloxacin were commenced as a part to manage her lower respiratory tract infection. Over next 2 hours, she started showing signs of neurological improvement and subsequent ABG post mechanical ventilation demonstrated significant improvement in acid-base status with pH corrected to 7.34 and pCO2 reduced to 60mmHg.
Noradrenaline was tapered and stopped by the evening on the same day. She was extubated the next morning and was started on non-invasive ventilation (NIV). She was initially stable on NIV, however, her condition deteriorated the next day with oxygen desaturation, bradycardia, and altered consciousness, leading to cardiac arrest. CPR was initiated along with airway control, with return of spontaneous circulation within a minute.
When we repeatedly inquired about her symptoms to the family, they provided us with a subtle history of ptosis that becomes prominent during the evening, dysarthria and difficulties with chewing and swallowing, all of which represented the bulbar symptoms. An antibody panel revealed negative Acetylcholine receptor binding (AChR) Antibody, but was positive for ANA and Muscle Specific Kinase (MuSK) Antibody.
She was then started on steroids Inj Hydrocortisone 50mg QID. The next day, she started showing improvements in neurological and respiratory parameters. She was extubated the next day following significant improvement in blood gas. Non-Invasive Mechanical Ventilation was initiated following extubation. She was gradually weaned off NIV to facemask and then to nasal cannula.
She was then started on Tab pyridostigmine 30mg BD and Tab Prednisolone in the tapering dose while stopping Inj hydrocortisone. Additionally, paraneoplastic panel was also sent, which yielded negative results.
She began pulmonary rehabilitation with incentive spirometry, and oxygen therapy was gradually tapered. She maintained normal CO2 levels, and after 19 days in the ICU and general ward, was discharged. Her plan included repeat blood gas tests, continued pyridostigmine, tapering prednisolone, and follow-up pulmonary function test, with a plan to start Azathioprine.
DISCUSSION
Myasthenia gravis is a rare auto-immune disorder characterized by the formation of antibodies against the nicotinic acetylcholine receptors at the neuromuscular junction or other postsynaptic muscle fibre components like muscle specific tyrosine kinase (MuSK). MuSk Antibodies were first time identified in a myasthenia gravis patient in 2001.^4^ Although rare, myasthenia gravis is the most common disorder of the neuromuscular junction, with an annual incidence of 0.25-2 patients per 100,000,5 and it is estimated to affect more than 700,000 patients worldwide.^6^
It is recognized that the type of antibodies present in the disease determines it's clinical behavior.^7^ Myasthenia patients with antibodies against acetylcholine receptors (AChR) have more of a variable presentation which includes weakness in the limbs more than the bulbar muscles involvement, marked ptosis, and associated thymoma in 80% of the cases.^7^ Whereas, myasthenia patients who have antibodies against MuSk, 80% of them show bulbar impairment,^4^ including dysphagia, dysphonia, chewing problems, slurred speech and tongue weakness/atrophy. Our patient, although didn't have muscle atrophy, but had other subtle bulbar symptoms. MuSk positive myasthenia are less commonly associated with thymoma or thymic hyperplasia and may show poor response to conventional therapy including thymectomy and pyridostigmine. However, more than 50% patients show symptomatic stability and remission when treated with a combination of AChE-I like pyridostigmine and a steroid.^8^ In addition, they are more prone to myasthenia crisis.^9^
Myasthenia crisis is a life-threatening complication of Myasthenia gravis. Early intubation and mechanical ventilation forms the mainstay in the management of myasthenia crisis.^1^ Post extubation NIV can be used to prevent re-intubation in Myasthenia crisis.^10^ Besides early mechanical ventilation, specific immunotherapy consisting of Plasmapheresis or Human IVIg is considered as a part of standard of care in patients with myasthenia crisis,^10^ and results in improvement in almost 70% of myasthenic patients with severe weakness.^1^ In our patient, plasmapheresis or IVIg was not considered to begin with due to the initial lack of suspicion of MG, with the acute presentation dominated by metabolic acidosis, sepsis, and comorbid conditions. Following confirmation of MuSK antibody positivity, corticosteroid therapy was initiated, resulting in rapid clinical improvement and therefore negating the need for plasmapheresis or IVIg.
Although myasthenia crisis can occur spontaneously in 1/3rd of the patients, the most common precipitant is infection, most commonly the bacterial pneumonia.^5^ Besides, other triggers being reduction of medication dose, pregnancy, perimenstrual period and certain medications like antibiotics (aminoglycosides, macrolides, fluoroquinolones, polymyxin), antiepileptics (phenytoin, gabapentin) and steroids.^5,11^ Steroid might sound paradoxical as steroids are also used in the management of Myasthenia crisis, but the initial treatment with steroids can lead to worsening symptoms in almost half of the patients and can lead to myasthenia crisis in 9-18% of patients.^12^ However, our case highlights a rapid and favourable response to early steroid initiation. This suggests that in selected cases, particularly under close monitoring and with the appropriate clinical context, steroids can be an effective initial treatment, potentially circumventing the need for more invasive therapies like IVIG or plasmapheresis.
The median duration of hospital stay in patients with myasthenia crisis is about 17-35 days.^1^ The mortality rate in myasthenia crisis patients presenting to hospital lies around 5%,^1^ however, it stands around 9.5% for MuSK positive myasthenia crisis.^8^ The cause of death being primarily sepsis, cardiac arrest, multiple organ failure and ARDS.^1^
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Claytor B Cho S Li Y Myasthenic Crisis Muscle & Nerve.2023 Apr 2868181910.1002/mus.2783237114503 · doi ↗ · pubmed ↗
- 2Shiozumi Tadaharu Okada N Matsuyama T Yoshihiro Yamahata Ohta B Anti-Musde-Specific Kinase (Mu SK) Antibody-Positive Myasthenia Gravis Presenting With Dyspnea in an Elderly Woman: A Case Report.Cureus [Internet].2023 Dec 1310.7759/cureus.5048038222201 PMC 10786710 · doi ↗ · pubmed ↗
- 3Lupica A Di Stefano V Iacono S Lanza P Brighina F Evaluation of Comorbidities in Myasthenia Gravis: The Experience of an Italian Center.Journal of the Neurological Sciences [Internet].2021 Oct 2024 Dec 742911837310.1016/j.jns.2021.118373 · doi ↗
- 4Rodolico C Bonanno C Toscano A Vita G Mu SK-Associated Myasthenia Gravis: Clinical Features and Management.Frontiers in Neurology [Internet].2020 Jul 231166010.3389/fneur.2020.0066032793097 PMC 7390870 · doi ↗ · pubmed ↗
- 5Wendell LC Levine JM Myasthenic Crisis.The Neurohospitalist.2011 Jan 2019 Oct 1511162210.1177/194187521038291823983833 PMC 3726100 · doi ↗ · pubmed ↗
- 6Payus AO Leow Wen Hsiang J Leong JQ Ibrahim A Raymond AA Myasthenic Crisis as the First Presentation of Myasthenia Gravis: A Case Report.American Journal of Case Reports.2020 Dec 72210.12659/AJCR.92841933468985 PMC 7823149 · doi ↗ · pubmed ↗
- 7García Fernández José M. Fernández-Valiñas A Hernández D Orozco J Lugo A Myasthenic Crisis in an Elderly Patient with Positive Antibodies against Acetylcholine and Anti-Mu SK, Successfully Treated with Noninvasive Mechanical Ventilation.2015 Jan 10.1155/2015/624718 PMC 468988926783473 · doi ↗ · pubmed ↗
- 8Huang Q Li F Zhao S Spotlight on Mu SK-Positive Myasthenia Gravis: Clinical Characteristics, Treatment, and Outcomes.BMC Neurology.2022 Mar 422110.1186/s 12883-022-02593-635246057 PMC 8895578 · doi ↗ · pubmed ↗
